Jazz Pharma Buying Experimental Narcolepsy Drug
Jazz Pharmaceuticals said Monday it is acquiring an experimental narcolepsy drug in a deal that could be worth more than $397 million.
The drug is called ADX-N05, and it is being developed by Aerial BioPharma. The drug is intended to treat daytime sleepiness in narcolepsy patients, and Jazz said it wants to start late-stage testing as soon as possible.
The Irish drugmaker agreed to pay Aerial BioPharma $125 million upfront, and it could make another $272 million in payments if the drug reaches development milestones and sales targets. Aerial BioPharma will also get royalties on sales if the drug is approved.
And this is why-
FDA grants orphan designation to Aerial BioPharma’s ARL-N05 for treatment of narcolepsy
(same drug, different name)
More of the same duplicitous thievery from Jazz- they are counting on being able to charge whatever the hell they please, and having taxpayers subsidize the bill.Aerial’s Exec VP of Drug and Development Gary Bream said ADX-NO5 is chemically distinct from modafinil and amphetamines, which (also) target the noradrenergic and dopaminergic pathways. He said it is too soon to know if it offers benefits over existing treatments.And they haven't tested that. Only tested against placebo.
